Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 6 | 3 |
| List of Figures | 9 | 2 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Introduction | 11 | 1 |
| Overview | 11 | 1 |
| GBI Research Report Guidance | 11 | 1 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Market Overview | 12 | 10 |
| Introduction | 12 | 1 |
| Types of Transplant | 12 | 1 |
| Autograft | 12 | 1 |
| Allograft | 12 | 1 |
| Isograft | 12 | 1 |
| Xenograft | 12 | 1 |
| Transplant Rejection | 13 | 1 |
| Hyperacute Rejection | 13 | 1 |
| Acute Rejection | 13 | 1 |
| Chronic Rejection | 13 | 1 |
| Immunosuppressive Drug Therapy | 13 | 1 |
| Classification of Immunosuppressant Drugs | 13 | 1 |
| Immunosuppressant Drug Therapy Monitoring | 14 | 1 |
| Market Forecast | 15 | 1 |
| Market Share by Disease Sector | 16 | 1 |
| Market Share by Geography | 17 | 1 |
| Annual Cost of Therapy | 18 | 1 |
| Target Population | 19 | 1 |
| Solid Organ Transplant Immunosuppressant Market Drivers and Restraints | 20 | 1 |
| Drivers | 20 | 1 |
| Improved Organ Preservation Techniques, Immunosuppressive Therapy and Advanced Surgical Techniques | 20 | 1 |
| Better Understanding of Immunological Mechanisms | 20 | 1 |
| Restraints | 21 | 1 |
| Ethical and Philosophical Barriers | 21 | 1 |
| Lack of Knowledge Regarding Organ Transplants amongst Prospective Donors | 21 | 1 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Geographical Landscape | 22 | 11 |
| The US | 22 | 1 |
| Introduction | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Therapy | 23 | 1 |
| Target Population | 24 | 1 |
| Top Five Countries of Europe | 25 | 1 |
| Introduction | 25 | 1 |
| Revenue | 25 | 2 |
| Annual Cost of Therapy | 27 | 1 |
| Target Population | 28 | 1 |
| Japan | 29 | 1 |
| Introduction | 29 | 1 |
| Revenue | 29 | 1 |
| Annual Cost of Therapy | 30 | 1 |
| Target Population | 31 | 2 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Therapeutic Landscape | 33 | 18 |
| Heart Transplant Market | 33 | 1 |
| Introduction | 33 | 1 |
| Revenue | 33 | 1 |
| Annual Cost of Therapy | 34 | 1 |
| Target Population | 35 | 1 |
| Lung Transplant Market | 36 | 1 |
| Introduction | 36 | 1 |
| Revenue | 36 | 2 |
| Annual Cost of Therapy | 38 | 1 |
| Target Population | 39 | 1 |
| Kidney Transplant Market | 40 | 1 |
| Introduction | 40 | 1 |
| Revenue | 40 | 1 |
| Annual Cost of Therapy | 41 | 1 |
| Target Population | 42 | 1 |
| Liver Transplant Market | 43 | 1 |
| Introduction | 43 | 1 |
| Revenue | 43 | 2 |
| Annual Cost of Therapy | 45 | 1 |
| Target Population | 46 | 1 |
| Pancreas Transplant Market | 47 | 1 |
| Introduction | 47 | 1 |
| Revenue | 47 | 2 |
| Annual Cost of Therapy | 49 | 1 |
| Target Population | 50 | 1 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Product Pipeline Analysis | 51 | 13 |
| Research and Development (R&D) Pipeline by Indication | 51 | 1 |
| R&D Pipeline by Phase | 52 | 1 |
| R&D Pipeline - Heart Transplant | 53 | 1 |
| Overview | 53 | 1 |
| Pre-Clinical Phase | 54 | 1 |
| Phase II | 54 | 1 |
| Phase III | 54 | 1 |
| R&D Pipeline - Lung Transplant | 55 | 1 |
| Overview | 55 | 1 |
| Pre-Clinical Phase | 56 | 1 |
| Phase II | 56 | 1 |
| Phase III | 56 | 1 |
| R&D Pipeline - Kidney Transplant | 57 | 1 |
| Overview | 57 | 1 |
| Pre-Clinical Phase | 58 | 1 |
| Phase I | 58 | 1 |
| Phase II | 58 | 1 |
| Phase III | 59 | 1 |
| R&D Pipeline - Liver Transplant | 60 | 1 |
| Overview | 60 | 1 |
| Pre-Clinical Phase | 60 | 1 |
| Phase II | 61 | 1 |
| Phase I | 61 | 1 |
| Pre-Clinical Phase | 61 | 1 |
| R&D Pipeline - Pancreas Transplant | 62 | 1 |
| Overview | 62 | 1 |
| Phase II | 63 | 1 |
| Phase III | 63 | 1 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Marketed Products | 64 | 5 |
| Prograf | 64 | 1 |
| Overview | 64 | 1 |
| Safety | 64 | 1 |
| Efficacy | 64 | 1 |
| Liver Transplantation | 64 | 1 |
| Kidney Transplantation | 65 | 1 |
| Cellcept | 65 | 1 |
| Overview | 65 | 1 |
| Safety | 65 | 1 |
| Efficacy | 65 | 1 |
| Renal Transplant | 65 | 1 |
| Cardiac Transplant | 66 | 1 |
| Hepatic Transplant | 66 | 1 |
| Results | 66 | 1 |
| Myfortic | 66 | 1 |
| Overview | 66 | 1 |
| Safety | 66 | 1 |
| Efficacy | 67 | 1 |
| Neoral | 67 | 1 |
| Overview | 67 | 1 |
| Safety | 67 | 1 |
| Efficacy | 67 | 1 |
| Zenapax | 68 | 1 |
| Overview | 68 | 1 |
| Safety | 68 | 1 |
| Efficacy | 68 | 1 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Competitive Landscape | 69 | 6 |
| F. Hoffman La Roche | 69 | 1 |
| Overview | 69 | 1 |
| Marketed Products | 69 | 1 |
| SWOT Analysis | 70 | 1 |
| Novartis AG | 71 | 1 |
| Overview | 71 | 1 |
| Marketed Products | 71 | 1 |
| SWOT Analysis | 72 | 1 |
| Genzyme Corporation | 72 | 1 |
| Overview | 72 | 1 |
| Marketed Products | 72 | 1 |
| SWOT Analysis | 73 | 1 |
| Astellas Pharma Inc. | 73 | 1 |
| Overview | 73 | 1 |
| Marketed Products | 73 | 1 |
| SWOT Analysis | 74 | 1 |
| Solid Organ Transplant Immunosuppressant Market to 2018 - Strategic Consolidations | 75 | 7 |
| Segmentation by Type | 75 | 1 |
| Segmentation by Year | 76 | 1 |
| Segmentation by Indication | 77 | 1 |
| Segmentation by Geography | 78 | 1 |
| Segmentation by Deal Value | 79 | 1 |
| Major M&As | 80 | 1 |
| Major Licensing Agreements | 80 | 1 |
| Major Co-Development Deals | 81 | 1 |
| Solid Organ Transplant Immunosuppressant Market to 2018 -Appendix | 82 | 6 |
| Market Definitions | 82 | 1 |
| Abbreviations | 82 | 1 |
| Research Methodology | 82 | 5 |
| Coverage | 82 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Therapeutic Landscape | 83 | 1 |
| Epidemiology-based Forecasting | 84 | 1 |
| Market Size by Geography | 85 | 1 |
| Geographical Landscape | 86 | 1 |
| Pipeline Analysis | 86 | 1 |
| Competitive Landscape | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 86 | 1 |
| Sources | 87 | 1 |